Nukkleus Stock Performance
| NUKKW Stock | 0.03 0.00 0.00% |
Nukkleus holds a performance score of 7 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -0.31, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Nukkleus are expected to decrease at a much lower rate. During the bear market, Nukkleus is likely to outperform the market. Use Nukkleus variance and rate of daily change , to analyze future returns on Nukkleus.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Nukkleus are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal forward-looking signals, Nukkleus showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Nukkleus Inc.s Price Is Right But Growth Is Lacking After Shares Rocket percent - Simply Wall St | 11/13/2024 |
2 | Nukkleus Secures 10M Private Placement to Acquire Iron Dome Defense Supplier RIMON - StockTitan | 12/18/2024 |
| Begin Period Cash Flow | 1.2 M |
Nukkleus |
Nukkleus Relative Risk vs. Return Landscape
If you would invest 3.01 in Nukkleus on September 22, 2024 and sell it today you would earn a total of 0.00 from holding Nukkleus or generate 0.0% return on investment over 90 days. Nukkleus is currently producing 3.4459% returns and takes up 33.9354% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Nukkleus, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Nukkleus Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nukkleus' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nukkleus, and traders can use it to determine the average amount a Nukkleus' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1015
| Best Portfolio | Best Equity | |||
| Good Returns | NUKKW | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 33.94 actual daily | 96 96% of assets are less volatile |
Expected Return
| 3.45 actual daily | 68 68% of assets have lower returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Nukkleus is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nukkleus by adding it to a well-diversified portfolio.
Nukkleus Fundamentals Growth
Nukkleus Stock prices reflect investors' perceptions of the future prospects and financial health of Nukkleus, and Nukkleus fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nukkleus Stock performance.
| Return On Equity | -0.75 | ||||
| Return On Asset | -1.15 | ||||
| Profit Margin | (2.53) % | ||||
| Operating Margin | (7.94) % | ||||
| Current Valuation | 330.32 M | ||||
| Price To Sales | 347.25 X | ||||
| Revenue | 16.22 M | ||||
| EBITDA | (1.49 M) | ||||
| Net Income | (11.85 M) | ||||
| Total Debt | 3.65 M | ||||
| Book Value Per Share | (6.61) X | ||||
| Cash Flow From Operations | 1.62 M | ||||
| Earnings Per Share | (0.02) X | ||||
| Market Capitalization | 3.73 B | ||||
| Total Asset | 18.36 M | ||||
| Retained Earnings | (14.34 M) | ||||
| Working Capital | (3.79 M) | ||||
About Nukkleus Performance
Evaluating Nukkleus' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Nukkleus has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nukkleus has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.41) | (1.48) | |
| Days Of Inventory On Hand | (57.25) | (60.12) | |
| Return On Capital Employed | (1.18) | (1.12) | |
| Return On Assets | (0.79) | (0.83) | |
| Return On Equity | (1.71) | (1.62) |
Things to note about Nukkleus performance evaluation
Checking the ongoing alerts about Nukkleus for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nukkleus help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nukkleus is way too risky over 90 days horizon | |
| Nukkleus has some characteristics of a very speculative penny stock | |
| Nukkleus appears to be risky and price may revert if volatility continues | |
| Nukkleus was previously known as Brilliant Acquisition and was traded on NASDAQ Exchange under the symbol BRLIW. | |
| The company reported the revenue of 16.22 M. Net Loss for the year was (11.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Latest headline from news.google.com: Nukkleus Secures 10M Private Placement to Acquire Iron Dome Defense Supplier RIMON - StockTitan |
- Analyzing Nukkleus' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nukkleus' stock is overvalued or undervalued compared to its peers.
- Examining Nukkleus' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nukkleus' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nukkleus' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nukkleus' stock. These opinions can provide insight into Nukkleus' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Nukkleus Stock Analysis
When running Nukkleus' price analysis, check to measure Nukkleus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nukkleus is operating at the current time. Most of Nukkleus' value examination focuses on studying past and present price action to predict the probability of Nukkleus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nukkleus' price. Additionally, you may evaluate how the addition of Nukkleus to your portfolios can decrease your overall portfolio volatility.